| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 12/18/2001 | US6331527 Promoter smooth muscle cell expression |
| 12/18/2001 | US6331525 Targeted delivery of genes encoding interferon |
| 12/18/2001 | US6331433 Human T cell leukemia cell line designated D1.1 |
| 12/18/2001 | US6331406 Human enbryonic germ cell and methods of use |
| 12/18/2001 | US6331301 Isolated dna sequences which encodes amino acid sequence in protein; |
| 12/18/2001 | US6331298 Wound healing and treatment of fibrotic disorders |
| 12/18/2001 | US6331286 Methods for high energy phototherapeutics |
| 12/18/2001 | US6331175 Method and kit for imaging and treating organs and tissues |
| 12/18/2001 | CA2221448C Antisense oligonucleotide modulation of raf gene expression |
| 12/18/2001 | CA2220182C Method of altering the contents of eggs |
| 12/18/2001 | CA2213815C Pyrrolidinyl hydroxamic acid compounds and their production process |
| 12/18/2001 | CA2202484C Use of indole derivatives for the treatment of various diseases |
| 12/18/2001 | CA2192665C Methods of lightening hyperpigmented regions in mammalian skin |
| 12/18/2001 | CA2178161C Indole derivatives |
| 12/18/2001 | CA2160725C Process for the preparation of a tetrazole derivative in two crystalline forms and novel crystalline form of said derivative |
| 12/18/2001 | CA2083143C Process for the preparation of 7.alpha.-alkoxycephem derivatives |
| 12/18/2001 | CA2031897C Carbamoyl derivatives |
| 12/13/2001 | WO2001094952A2 Methods and compositions for modulating oxidized ldl transport |
| 12/13/2001 | WO2001094951A2 Inhibitors of c-reactive protein induced inflammation |
| 12/13/2001 | WO2001094645A1 Two-hybrid assay that detects hiv-1 reverse transcriptase dimerization |
| 12/13/2001 | WO2001094636A2 Compositions, kits, and methods for identification and modulation of type i diabetes |
| 12/13/2001 | WO2001094616A1 Protein markers for pharmaceuticals and related toxicity |
| 12/13/2001 | WO2001094613A2 Methods and compounds for influencing beta3 integrin-dependent intracellular processes |
| 12/13/2001 | WO2001094612A2 Method for identifying medically valuable active substances |
| 12/13/2001 | WO2001094586A2 Non-agonistic antibodies to human gp39, compositions containing, and therapeutic use thereof |
| 12/13/2001 | WO2001094581A1 Tumour suppressor and uses thereof |
| 12/13/2001 | WO2001094420A1 Identification and use of human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury |
| 12/13/2001 | WO2001094413A2 B7-related nucleic acids and polypeptides and their uses for immunomodulation |
| 12/13/2001 | WO2001094391A2 Intracellular signaling proteins |
| 12/13/2001 | WO2001094381A2 Novel compounds of the n-acylamino-amide family, compositions comprising same, and uses |
| 12/13/2001 | WO2001094380A2 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
| 12/13/2001 | WO2001094368A1 2-aminocarbonyl-9h-purine derivatives |
| 12/13/2001 | WO2001094367A1 Malto-oligosaccharide derivatives and use thereof |
| 12/13/2001 | WO2001094351A1 Caspase inhibitors and uses thereof |
| 12/13/2001 | WO2001094347A1 Tetracyclic diketopiperazine compounds as pdev inhibitors |
| 12/13/2001 | WO2001094346A1 1,3,8-TRIAZA-SPIRO'4,5!DECAN-4-ONE DERIVATIVES AS NEUROKININ RECEPTOR ANTAGONISTS |
| 12/13/2001 | WO2001094345A2 Derivatives of 2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione |
| 12/13/2001 | WO2001094326A1 Novel thiazolidinedione derivatives and use thereof as drugs |
| 12/13/2001 | WO2001094321A1 Bicyclic cyclohexylamines and their use as nmda receptor antagonists |
| 12/13/2001 | WO2001094312A2 Indolinone derivatives as protein kinase/phosphatase inhibitors |
| 12/13/2001 | WO2001094311A1 Cytoprotectors |
| 12/13/2001 | WO2001094307A1 Propanolaminotetralines, preparation thereof and compositions containing same |
| 12/13/2001 | WO2001094301A2 Factor viia inhibitory (thio)urea derivatives, their preparation and their use |
| 12/13/2001 | WO2001093983A1 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 12/13/2001 | WO2001093909A2 Cancer treatment composition containing an anti-neoplastic agent and a pde4 inhibitor |
| 12/13/2001 | WO2001093893A2 The use of copolymer 1 and related peptides and polypeptides and t cells treated therewith for neuroprotective therapy |
| 12/13/2001 | WO2001093885A1 Therapeutic agents - ii |
| 12/13/2001 | WO2001093884A1 Therapeutic agents - i |
| 12/13/2001 | WO2001093883A1 Therapeutic agents - iii |
| 12/13/2001 | WO2001093879A1 Biologically active agents and drugs |
| 12/13/2001 | WO2001093867A1 4,5-dihydro-thiazo-2-ylamine derivatives and their use as no-synthase inhibitors |
| 12/13/2001 | WO2001093862A1 Prostaglandin compounds for treating congestive heart failure |
| 12/13/2001 | WO2001093860A1 Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same |
| 12/13/2001 | WO2001093856A1 Medical composition kit for treating lesioned abnormal tissue |
| 12/13/2001 | WO2001093846A2 Method for treating respiratory disorders associated with pulmonary elastic fiber injury comprising the use of clycosaminoglycans |
| 12/13/2001 | WO2001093845A2 Carboxyalkylether-acat inhibitor combinations |
| 12/13/2001 | WO2001093843A2 Benzoic acid esters having antiplasmid effect |
| 12/13/2001 | WO2001093841A2 Barbituric acid analogs as therapeutic agents |
| 12/13/2001 | WO2001093828A1 The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
| 12/13/2001 | WO2001093826A1 Biocompatible synthetic polymer preparations |
| 12/13/2001 | WO2001085145A8 A pharmaceutical composition and method of treatment of diseases of cognitive dysfunction in a mammal |
| 12/13/2001 | WO2001047508A3 Combination of trimebutine with an opioid analgesic |
| 12/13/2001 | WO2001045637A3 Novel 4(piperazinyl (8-quinolinyl)metyl)benzamides |
| 12/13/2001 | WO2001044445A3 Human lyases and associated proteins |
| 12/13/2001 | WO2001043694A3 Compositions and methods for caspase-induced apoptosis |
| 12/13/2001 | WO2001041709A3 Methods for treating cell death diseases and inflammation |
| 12/13/2001 | WO2001041701A3 The combination of a serotonin reuptake inhibitor and a 5-ht2c antagonist, inverse agonist or partial agonist |
| 12/13/2001 | WO2001040243A3 Partial or full a1 agonists - n6 heterocyclic 5'-thio substituted adenosine derivatives |
| 12/13/2001 | WO2001039742A3 Methods for making sustained-release pharmaceutical compositions of ergot alkaloids having improved bioavailability and compositions thereof |
| 12/13/2001 | WO2001037820A3 Ionizable indolinone derivatives and their use as ptk ligands |
| 12/13/2001 | WO2001035899A3 Inhibitors of helicobacter pylori induced gastrointestinal diseases |
| 12/13/2001 | WO2001030987A3 Tankyrase h, compositions involved in the cell cycle and methods of use |
| 12/13/2001 | WO2001028577A3 Inhibition of cell motility and angiogenesis by inhibitors of the grb2 sh2-domain |
| 12/13/2001 | WO2001027136A3 Peptides which stimulate the immune response and tissue regeneration |
| 12/13/2001 | WO2001026637A3 Transdermal therapeutic system for administering acetylsalicylic acid and/or salicylic acid |
| 12/13/2001 | WO2001021008A3 Method for increasing pet activity |
| 12/13/2001 | WO2001020026A3 POLYMORPHISMS IN THE HUMAN hPXR GENE AND THEIR USE IN DIAGNOSTIC AND THERAPEUTIC APPLICATIONS |
| 12/13/2001 | WO2001018181A3 Enzyme inhibitors |
| 12/13/2001 | WO2000033857A9 Cancer treatment composition and method using natural plant essential oils |
| 12/13/2001 | US20010051722 Aminoaryl Oxazolidinone N-oxides |
| 12/13/2001 | US20010051708 Purifying antibody; prepare antibody suspension, mix with water soluble liquid, recover clarified antibody, apply to chromatography column, elute antibody, concentrate antibody |
| 12/13/2001 | US20010051656 Co-administration of a prostaglandin and an androgenic agent in the treatment of female sexual dysfunction |
| 12/13/2001 | US20010051646 Method for the improvement of islet signaling in diabetes mellitus and for its prevention |
| 12/13/2001 | US20010051636 Combination treatment for inhibiting bone loss |
| 12/13/2001 | US20010051626 Substituted 1,2,3,4-tetrahydronaphthalene derivatives |
| 12/13/2001 | US20010051623 8-(Piperidin-4-yl- or piperazin-1-yl)-2-substituted-tetralin derivatives; selective effect at a subgroup of 5-hydroxytryptamine receptors, h5-HT1B receptors (previously 5-HT1D beta); antagonists; mood disorders, antianxiolytic |
| 12/13/2001 | US20010051616 Administering alendronate sodium |
| 12/13/2001 | US20010051604 Mixture containing stabilizers, sodium chloride, buffer and surfactants |
| 12/13/2001 | US20010051601 Use of growth hormone in low dose |
| 12/13/2001 | US20010051361 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
| 12/13/2001 | US20010051155 Using immunoglobulin binding epitopes |
| 12/13/2001 | US20010051146 Agent for preventing and/or treating multiple organ failure |
| 12/13/2001 | EP1143806A3 Method for increasing pet activity |
| 12/13/2001 | DE10101324C1 New 1-(dimercaptoalkyl)-quinazoline-2,4(1H,3H)-diones, are stable matrix metalloproteinase inhibitors useful e.g. for treating rheumatism, tumor metastasis or sunburn |
| 12/13/2001 | DE10027887A1 Verbindungen mit einer Sulfonamidgruppe und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen Compounds having a sulfonamide group, these compounds and pharmaceutical compositions containing them |
| 12/13/2001 | DE10025609A1 Transfektionssystem Transfection |
| 12/13/2001 | CA2810249A1 Identification and use of human bone marrow-derived endothelial progenitor cell to improve myocardial function after ischemic injury |
| 12/13/2001 | CA2413906A1 Carboxyalkylether-acat inhibitor combinations |
| 12/13/2001 | CA2412436A1 Identification and use of human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury |
| 12/13/2001 | CA2412386A1 Two-hybrid assay that detects hiv-1 reverse transcriptase dimerization |